Dual checkpoint blockade with TACE in intermediate-stage hepatocellular carcinoma: safety, efficacy, and ctDNA correlates from a phase II study
This project is to evaluate TACE combined with durvalumab/tremelimumab, incorporating hepatic function monitoring and short-fragment circulating tumor DNA (ctDNA) analysis for early response prediction.